A 1-year analysis of adverse events following COVID-19 vaccination in Lebanon: a retrospective study

A 1-year analysis of adverse events following COVID-19 vaccination in Lebanon: a retrospective study

Abstract Background Since the deployment of Coronavirus Disease 2019 (COVID-19) vaccines, skepticism about the safety, incidence, and severity of Adverse Events Following Immunization (AEFI) was a concern. The study has two main objectives. First, to analyze AEFIs following COVID-19 vaccines (Pfizer...

Full description

Bibliographic Details
Main Authors:	Abeer Zeitoun, Souheil Hallit, Sirine Chehade, Aya Ibrahim, Maya Helali, Carla Allam, Rita Karam
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2023-02-01
Series:	Journal of Pharmaceutical Policy and Practice
Subjects:	Pharmacovigilance COVID-19 vaccines Adverse event following immunization SARS-CoV-2
Online Access:	https://doi.org/10.1186/s40545-023-00528-1

Similar Items

Vaccination process evaluation at COVID-19 vaccination centers in Lebanon: a national study
by: Abeer Zeitoun, et al.
Published: (2022-12-01)

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
by: Yamin Shu, et al.
Published: (2023-05-01)

Adverse events in patients with advanced urothelial carcinoma treated with erdafitinib: a retrospective pharmacovigilance study
by: Tengfei Yuan, et al.
Published: (2023-11-01)

Adverse events following immunization associated with coronavirus disease 2019 (COVID-19) vaccines: A descriptive analysis from VigiAccess
by: Peter Yamoah, et al.
Published: (2022-11-01)

A real-world study of antifibrotic drugs-related adverse events based on the United States food and drug administration adverse event reporting system and VigiAccess databases
by: Menglin He, et al.
Published: (2024-02-01)

A Retrospective Evaluation of Self-Reported Adverse Events Following Immunization with Different COVID-19 Vaccines in Türkiye
by: Sultan Mehtap Büyüker, et al.
Published: (2023-01-01)

Post-marketing surveillance of adverse events following measles, mumps, rubella and varicella (MMRV) vaccine: retrospecive study in apulia region (ITALY), 2009-2017
by: Pasquale Stefanizzi, et al.
Published: (2020-08-01)

Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS)
by: Pan Ma, et al.
Published: (2022-11-01)

Awareness of Digital Reporting of Adverse Drug Events among Health Care Professionals
by: Shweta Sharma, et al.
Published: (2023-09-01)

Adverse event reporting practices in drug-resistant tuberculosis facilities across South Africa
by: Razia Gaida, et al.
Published: (2023-12-01)

A Retrospective Cross-Sectional Study Assessing Self-Reported Adverse Events following Immunization (AEFI) of the COVID-19 Vaccine in Bangladesh
by: Arifa Sultana, et al.
Published: (2021-09-01)

New Adverse Drug Reaction Signals from 2017 to 2021—Genuine Alerts or False Alarms?
by: Yoon Kong Loke, et al.
Published: (2024-02-01)

Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS)
by: Lin Zhang, et al.
Published: (2023-11-01)

Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system
by: Rui Xiong, et al.
Published: (2023-09-01)

Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System
by: Yamin Shu, et al.
Published: (2022-06-01)

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for alpelisib
by: Yu Lin, et al.
Published: (2024-03-01)

Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS)
by: Si Su, et al.
Published: (2023-11-01)

Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System
by: Haoning Guo, et al.
Published: (2022-04-01)

A real-world disproportionality analysis of Everolimus: data mining of the public version of FDA adverse event reporting system
by: Bin Zhao, et al.
Published: (2024-03-01)

A real-world disproportionality analysis of mesalazine data mining of the public version of FDA adverse event reporting system
by: Mingdi Liu, et al.
Published: (2024-01-01)

Cardiovascular Adverse Events Associated with Monoclonal Antibody Products in Patients with COVID-19
by: Jingrui Zou, et al.
Published: (2022-11-01)

Adverse Drug Events Presented in Health Institutions in Monteria, Colombia, 2018–2021
by: Martínez M, et al.
Published: (2023-12-01)

Examining the safety of mirabegron: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database
by: Junwei Wang, et al.
Published: (2024-03-01)

ADVERSE EVENTS OF INTERFERONS WITH SYSTEMIC EFFECT
by: A. A. Toporov, et al.
Published: (2018-02-01)

Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system
by: Yankun Liang, et al.
Published: (2023-10-01)

Analysis of Azithromycin adverse events in COVID-19 Patients reported to Iraqi Pharmacovigilance center in 2020
by: Yasir A. Noori, et al.
Published: (2022-10-01)

Under-Reporting of Adverse Drug Reactions in Finland and Healthcare Professionals’ Perspectives on How to Improve Reporting
by: Andreas Sandberg, et al.
Published: (2022-05-01)

Adverse events related to oral hormonal contraceptive use in undergraduate pharmacy students: a cross-sectional study
by: Helena Constância de Melo Tozetto, et al.
Published: (2023-01-01)

Pharmacological Evaluation of Signals of Disproportionality Reporting Related to Adverse Reactions to Antiepileptic Cannabidiol in VigiBase
by: Fabrizio Calapai, et al.
Published: (2023-10-01)

Trends of Adverse Events Following Immunization (AEFI) Reports of Human Papillomavirus Vaccine in the Valencian Community—Spain (2008–2018)
by: Cecilia M. Egoavil, et al.
Published: (2020-03-01)

Evaluating the costs of adverse drug events in hospitalized patients: a systematic review
by: Maxime Durand, et al.
Published: (2024-02-01)

Reporting Antimicrobial-Related Adverse Drug Events in Jordan: An Analysis from the VigiBase Database
by: Nizar Mahmoud Mhaidat, et al.
Published: (2023-03-01)

A real-world pharmacovigilance study of FDA adverse event reporting system events for diazepam
by: Weizhen He, et al.
Published: (2024-01-01)

A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib
by: Yan Wu, et al.
Published: (2023-08-01)

Characteristics of Adverse Events Following Immunization Reporting in Children: The Japanese Adverse Drug Event Report Database
by: Aoi Noda, et al.
Published: (2020-07-01)

Thoughts on fund compensation of adverse events following immunization in China
by: SU Ting, et al.
Published: (2022-04-01)

Oral Adverse Events Following COVID-19 Vaccination: Analysis of VAERS Reports
by: Abanoub Riad, et al.
Published: (2022-07-01)

Structure of Adverse Events Following Immunisation against Coronavirus Infection (COVID-19) in the Kyrgyz Republic
by: A. A. Zurdinova, et al.
Published: (2022-12-01)

Pharmacovigilance in Brazil: The Government Monitoring of Adverse Events Reported from COVID-19 Vaccine—A Narrative Review
by: Mariana Carvalho de Moraes, et al.
Published: (2024-02-01)

A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?
by: Zhiwei Cui, et al.
Published: (2023-10-01)